Retail Pharmacy Market Research Insights. June 2014

Transcription

1 Retail Pharmacy Market Research Insights June 2014

2 Sources of Information Pharmacy Tracking Study Q Nationwide survey conducted among 310 retail pharmacists from October December 2013 All respondents must have administered either ZOSTAVAX (Zoster Vaccine Live), PNEUMOVAX 23 (Pneumococcal Vaccine Polyvalent), or both, in the past month in order to qualify for the study Results have been weighted to reflect the mix of store types (national pharmacy chains, grocery chains, mass merchandisers, independents) among the measurable population Retail Pharmacy Attribute Tracking Study 15-minute survey conducted among 819 retail pharmacists from September December 2013 All respondents must have administered either ZOSTAVAX, PNEUMOVAX 23, or both, in the past month in order to qualify for the study All respondents work in a Project Evolve deployment territory

3 Sources of Information (cont d) Customer Journey Mapping Study The research included three phases with overlapping respondent sets: Quantitative Survey (n=147) Mobile Research (n=54) Qualitative Interviews (n=24) All respondents must have administered either ZOSTAVAX, PNEUMOVAX 23, or both, in the past month in order to qualify for the study

4 Important Information About ZOSTAVAX (Zoster Vaccine Live) About ZOSTAVAX ZOSTAVAX is a live attenuated virus vaccine indicated for prevention of herpes zoster (shingles) in individuals 50 years of age and older. ZOSTAVAX is not indicated for the treatment of zoster or postherpetic neuralgia. ZOSTAVAX should not be used for prevention of primary varicella infection (Chickenpox). Select Safety Information Vaccination with ZOSTAVAX does not result in protection of all vaccine recipients. ZOSTAVAX is contraindicated in: persons with a history of anaphylactic or anaphylactoid reaction to gelatin, neomycin, or any other component of the vaccine; persons with a history of primary or acquired immunodeficiencies; persons on immunosuppressive therapy; pregnant women or women of childbearing age. A reduced immune response to ZOSTAVAX was observed in individuals who received concurrent administration of PNEUMOVAX 23 (Pneumococcal Vaccine Polyvalent) and ZOSTAVAX compared with individuals who received these vaccines 4 weeks apart. Consider administration of the two vaccines separated by at least 4 weeks.

5 Important Information About ZOSTAVAX (Zoster Vaccine Live) Select Safety Information (continued) Serious vaccine-related adverse reactions that have occurred following vaccination with ZOSTAVAX include asthma exacerbation and polymyalgia rheumatica. Other serious adverse events reported following vaccination with ZOSTAVAX include cardiovascular events (congestive heart failure, pulmonary edema). Common adverse reactions occurring in 1% of vaccinated individuals during clinical trials include injection-site reactions (erythema, pain/tenderness, swelling, hematoma, pruritus, warmth) and headache. Transmission of vaccine virus may occur between vaccinees and susceptible contacts. Deferral should be considered in acute illness (for example, in the presence of fever) or in patients with active untreated tuberculosis. Before administering ZOSTAVAX, please read the Prescribing Information available at this presentation.

6 Important Information About PNEUMOVAX 23 (Pneumococcal Vaccine Polyvalent) About PNEUMOVAX 23 PNEUMOVAX 23 is a vaccine indicated for active immunization for the prevention of pneumococcal disease caused by the 23 serotypes contained in the vaccine (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F). PNEUMOVAX 23 is approved for use in persons 50 years of age or older and persons aged 2 years who are at increased risk for pneumococcal disease. PNEUMOVAX 23 will not prevent disease caused by capsular types of pneumococcus other than those contained in the vaccine. Select Safety Information Do not administer PNEUMOVAX 23 to individuals with a history of a hypersensitivity reaction to any component of the vaccine. Use caution and appropriate care in administering PNEUMOVAX 23 to individuals with severely compromised cardiovascular and/or pulmonary function in whom a systemic reaction would pose a significant risk.

7 Important Information About PNEUMOVAX 23 (Pneumococcal Vaccine Polyvalent) Select Safety Information (continued) The most common adverse reactions, reported in >10% of subjects vaccinated with PNEUMOVAX 23 in clinical trials, were: injection-site pain/soreness/tenderness, injection-site swelling/induration, headache, injection-site erythema, asthenia and fatigue, and myalgia. Vaccination with PNEUMOVAX 23 may not offer 100% protection from pneumococcal infection. Before administering PNEUMOVAX 23, please read the Prescribing Information available at this presentation.

8 Vaccination rates for selected ACIP-recommended adult vaccines Selected CDC Adult Vaccination Rates-United States, 2012 Vaccine/Population Estimated Vaccination Rate Herpes Zoster 1 Patients 60 years of age or older 20.1% Pneumococcal 1 Patients years of age (High Risk) Patients 65 years of age or older 20% 59.9% Influenza 2 ( Flu Season) Patients years of age 42.7% Patients 65 years of age or older 64.9% References: 1. Centers for Disease Control and Prevention (CDC). Noninfluenza Vaccination Coverage Among Adults United States, Morbidity and Mortality Weekly Report, p Centers for Disease Control and Prevention (CDC). Flu Vaccination Coverage, United States, Influenza Season. Data Sources: National Immunization Survey (NIS) and Behavioral Risk Factor Surveillance System (BRFSS) p2.

9 The majority of shingles vaccinations in the retail pharmacy setting are the result of patient-initiated conversations 1 Opportunity Shingles Vaccine Out of 1,000 visits of patients age 60+ to the pharmacy counter, on average Identification Patient comes to the pharmacy for the shingles vaccine Patient comes to the pharmacy for other reason Initiation (conversation about vaccine) with Rx 6 times A without Rx 6 times D Patient initiates conversation 8 times G RPh initiates conversation 5 times J Conversion (actual vaccination) 4 patients vaccinated B 70% conversion rate C 3 patients vaccinated E 50% conversion rate F 3 patients vaccinated H 41% conversion rate I 2 patients vaccinated K 33% conversion rate L Source: Pharmacy Tracking Study Q (n=310) Reference: 1. Data available on request from Merck, Professional Services-DAP, WP1-27, PO Box 4, West Point, PA Please specify information package VACC

10 Pharmacists initiate very few pneumococcal vaccine conversations 1 Opportunity Pneumococcal Vaccine Out of 1,000 visits of patients age 65+ to the pharmacy counter, on average Identification Patient comes to the pharmacy for the pneumococcal vaccine Patient comes to the pharmacy for other reason Initiation (conversation about vaccine) with Rx 3 times A without Rx 5 times D Patient initiates conversation 4 times G RPh initiates conversation 3 times J Conversion (actual vaccination) 2 patients vaccinated B 76% conversion rate C 2 patients vaccinated E 37% conversion rate F 2 patients vaccinated H 50% conversion rate I 1 patient vaccinated K 40% conversion rate L Source: Pharmacy Tracking Study Q (n=310) Reference: 1. Data available on request from Merck, Professional Services-DAP, WP1-27, PO Box 4, West Point, PA Please specify information package VACC

11 2014 Strategy Informed by Pharmacist, Physician and Consumer Research Insights Opportunities Challenges Opportunity On average, consumers shopped at pharmacies ~4 times per month (2010 data) 1 Pharmacists miss opportunities to engage with patients about vaccination Identification/ Discussion Recommendation Pharmacy vaccination infrastructure; influential PDMs promote more involvement and vaccination commitment RPh personal experience with shingles (e.g. loved one or patient); pharmacists belief in seriousness of disease Lack of time; concern of being viewed as pushy or selling vaccines Pharmacists perception that vaccine is expensive for the patient Vaccination Physician Rx/recommendation; disease/vaccine awareness Patient out-of-pocket costs too high; HCC wants to discuss with Physician/ family Sources: Pharmacy Tracking Study Q (n=306) Pharmacy Tracking Study Q (n=304) Pharmacy Tracking Study Q (n=310) 1. Pharmacy Satisfaction Pulse full industry report. March Boehringer Ingelheim Pharmaceuticals, Inc. Web site.

12 Significant opportunity exists to increase Shingles + Flu vaccination at the same visit in Pharmacy 1 Pharmacists Responses Re: Vaccine Co-Administration in the Retail Pharmacy Setting 86% A Mean % 47% B 19% C Mean % of pharmacists allowed to coadminister vaccines Source: Pharmacy Tracking Study Q (n=310) Mean % of patients eligible to receive Shingles + Flu vaccines Reference: 1. Data available on request from Merck, Professional Services-DAP, WP1-27, PO Box 4, West Point, PA Please specify information package VACC Mean % of eligible patients who receive the Shingles + Flu vaccine

13 Retail Pharmacy Attributes Nationally 1 Retail Pharmacy Attributes Nationally Percent of Pharmacists Who Agree Retail Pharmacies Mean % Does this pharmacy offer vaccine-specific events and/or initiatives? 69% A Does this pharmacy use processes and/or collaborative agreements? Is the Pharmacy District Manager highly engaged in vaccine decisions in the pharmacy? Does this pharmacy use internal systems to flag appropriate patients for vaccination? 50% B 46% C 41% D Does this pharmacy proactively communicate its vaccination services through other media? 2 through physician faxes? Has the pharmacy established a process to proactively identify potentially eligible vaccination candidates? Does this pharmacy have set goals for vaccinations (e.g., a certain number of eligible patients vaccinated in a given time period)? 31% E 59% F 55% G 71% E 1 Shown is the percent of National Pharmacy Chain, Grocery Chain, Mass Merchandiser, and Regional Chain pharmacists with an influential PDM (question not asked of Independent pharmacists) 2 Full wording: Promote vaccination through external advertising (e.g., newspaper, broadcast radio, internet, direct mail) Source: Pharmacy Tracking Study Q (n=310) Copyright 2014 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. All rights reserved. Reference: 1. Data available on request from Merck, Professional Services-DAP, WP1-27, PO Box 4, West Point, PA Please specify information package VACC